Primary Prevention
Bempedoic acid receives broader indications from FDA
Esperion Therapeutics announced the FDA approved broad label expansion for bempedoic acid and bempedoic acid/ezetimibe for CV risk reduction and LDL lowering in both primary and secondary prevention populations.
CMS risk reduction program lowered first-time heart attacks, strokes without raising costs
Data show CMS’ Million Hearts CVD Risk Reduction Model, which provided payments for CVD risk assessment and reduction, reduced incidence of first-time MIs and strokes over 5 years without significant changes in Medicare spending.
Statins for primary prevention provide similar protection among older vs. younger adults
Older individuals appeared to derive similar magnitude of LDL lowering and CV risk reduction from statin therapy initiation vs. younger patients, according to data from a large Danish study.
Gulati: Preventive cardiology ‘should be at the forefront’ of care
ARLINGTON, Texas — Prevention of CVD must be a top priority in health care, and professional societies must work together to improve the health of everyone before the onset of disease, according to a speaker.
ASPC congress to highlight all aspects of CVD prevention
The American Society for Preventive Cardiology Congress on CVD Prevention will be held Friday through Sunday and will emphasize inclusiveness by focusing on the “care of one and all” at risk for CVD.
In nonischemic cardiomyopathy requiring ICD, Black patients may have worse outcomes
In patients with an implantable cardioverter defibrillator for primary prevention, among those with nonischemic cardiomyopathy, Black patients were more likely to have arrhythmias, to receive ICD therapies and to die than white patients.
FDA expands inclisiran indication to primary prevention patients
The FDA approved a label update for inclisiran to include people with elevated LDL and other risk factors such as hypertension and diabetes who have not experienced a CV event, Novartis announced.
Statins appear to improve mortality in patients with high BP but no other CVD, diabetes
Statin use for primary prevention was associated with reduced risk for all-cause and CV death among patients with hypertension and no other CVD or diabetes vs. matched controls not on statin therapy, researchers reported.
‘Simply stunning’: Bempedoic acid may cut CVD risk for primary prevention patients by 30%
SAN DIEGO — In adults with elevated cardiovascular risk but without a prior clinical event and deemed statin intolerant, bempedoic acid reduced risk for major adverse CV events by 30% compared with placebo, researchers reported.
Insured status, cardiac care improved after state participation in Medicaid expansion
Within participating states, Medicaid expansion improved insurance coverage and CV health and reduced disparities in care, according to a meta-analysis.